SEC Form 4 · accession 0000899243-15-005120
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas E. Hughes
Officer — Chief Executive Officer · Director
Period of report
Sep 17, 2015
Accepted (ET)
Sep 21, 2015 · 9:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 17, 2015 | M | 4,874 | $2.45 | A | 23,320 | D | |
| Common StockF2,F1 | Sep 17, 2015 | S | 22,500 | $40.00 | D | 820 | D | |
| Common StockF1 | Sep 18, 2015 | M | 23,126 | $2.45 | A | 23,946 | D | |
| Common StockF2,F1 | Sep 18, 2015 | S | 23,126 | $45.00 | D | 820 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.45 | Sep 17, 2015 | M | 4,874 | D | — | Jun 12, 2023 | Common Stock | 4,874 | 183,681 | D |
| Stock Option (Right to Buy)F3 | $2.45 | Sep 18, 2015 | M | 23,126 | D | — | Jun 12, 2023 | Common Stock | 23,126 | 160,555 | D |
Explanation of responses
- F1Includes 428 shares acquired by the Reporting Person under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan (the "Plan") on June 30, 2015 and 392 shares acquired under the Plan on December 31, 2014.
- F2This sale of shares by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F325% of this option vested on December 19, 2013, and the remainder vests in equal monthly installments thereafter over 36 months.